Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00968071 |
Recruitment Status :
Completed
First Posted : August 28, 2009
Results First Posted : March 8, 2013
Last Update Posted : March 8, 2013
|
Sponsor:
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Conditions |
Acute Myelogenous Leukemia Myelodysplastic Syndrome |
Interventions |
Drug: Decitabine Drug: Gemtuzumab Ozogamicin |
Enrollment | 71 |
Participant Flow
Recruitment Details | Recruitment Period: 2/19/2008 through 5/12/2009. All participants recruited at UT MD Anderson Cancer Center. |
Pre-assignment Details |
Baseline Characteristics
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Gautam Borthakur M.D./Associate Proffesor |
Organization: | The University of Texas M. D. Anderson Cancer Center |
Phone: | 713-563-1586 |
EMail: | eharriso@mdanderson.org |
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00968071 History of Changes |
Other Study ID Numbers: |
2007-0882 |
First Submitted: | August 26, 2009 |
First Posted: | August 28, 2009 |
Results First Submitted: | February 4, 2013 |
Results First Posted: | March 8, 2013 |
Last Update Posted: | March 8, 2013 |